Last updated: November 6, 2026
Nafcillin sodium is a mature, generic, hospital-administered antibiotic used primarily for serious infections caused by methicillin-susceptible Staphylococcus aureus (MSSA). Its commercial market is driven by inpatient demand rather than branded prescribing. Patent protection and regulatory exclusivity do not materially restrict competition. Financial performance is constrained by low generic pricing, sterile-injectable manufacturing costs, hospital purchasing pressure, and competition from cefazolin, oxacillin, vancomycin, daptomycin, and other anti-infective agents.
Public companies generally do not report nafcillin sodium revenue as a separate product line. The financial trajectory is therefore best assessed through utilization, supplier participation, hospital formulary position, supply reliability, and generic injectable economics.
What is nafcillin sodium used for?
Nafcillin sodium is an antistaphylococcal penicillin administered by intravenous or intramuscular injection. It is indicated for infections caused by susceptible penicillinase-producing staphylococci, including MSSA infections involving the bloodstream, heart valves, bones, joints, skin, and soft tissue.[1]
The drug is not an oral product. Its use is concentrated in hospitals, outpatient parenteral antimicrobial therapy programs, and specialty infusion settings.
What infections drive nafcillin demand?
The principal demand categories are:
- MSSA bacteremia and infective endocarditis
- Osteomyelitis and septic arthritis
- Deep surgical-site and soft-tissue infections
- Hospital-acquired MSSA infections
- Selected central-line and device-associated infections
- Serious infections requiring prolonged intravenous therapy
Nafcillin is less relevant for methicillin-resistant S. aureus (MRSA), for which clinicians use agents such as vancomycin, daptomycin, linezolid, or ceftaroline depending on the infection and patient profile.[2]
What is the FDA regulatory status of nafcillin sodium?
Nafcillin sodium is an FDA-approved prescription injectable antibiotic sold primarily through abbreviated new drug applications (ANDAs) and generic labeling. The product is supplied as nafcillin sodium for injection in sterile vials, with strength and presentation varying by manufacturer.[1]
The product does not depend on a current branded new-drug application for market access. Generic suppliers must demonstrate pharmaceutical equivalence and bioequivalence where applicable, meet current good manufacturing practice requirements, and maintain injectable-product quality systems.
Is nafcillin sodium a biologic or biosimilar product?
No. Nafcillin sodium is a small-molecule drug. Biosimilar regulation under the Public Health Service Act is not relevant. Competition occurs through the generic drug pathway under the Federal Food, Drug, and Cosmetic Act.
What dosage forms are commercially relevant?
The commercially relevant form is sterile injectable nafcillin sodium. There is no commercially important oral nafcillin market in the United States. The injectable format raises manufacturing and supply risks because production requires sterile filling, validated aseptic processing, container-closure integrity, and compliance with injectable-drug quality standards.
What patents protect nafcillin sodium?
No meaningful active composition-of-matter patent protection remains for nafcillin sodium. The molecule has been used clinically for decades, and any original compound patent terms expired long ago.
The current competitive position is not controlled by:
- A live compound patent
- A branded formulation patent
- Pediatric exclusivity
- New chemical entity exclusivity
- Orphan-drug exclusivity
- A major method-of-use patent estate
The FDA Orange Book remains the principal source for patents and exclusivity associated with approved drug products. Nafcillin sodium’s commercial market is generally treated as an unprotected generic injectable market rather than a patent-protected branded market.[3]
What formulation patents protect nafcillin sodium?
No widely recognized formulation patent is a material barrier to generic nafcillin sodium injection. Product differentiation is more likely to arise from vial configuration, packaging, reconstitution instructions, manufacturing reliability, and distribution contracts than from enforceable exclusivity.
Manufacturers may hold process know-how or confidential manufacturing information. Those protections can affect supply economics but do not prevent other companies from manufacturing a therapeutically equivalent product.
What method-of-use patents protect nafcillin sodium?
There is no broadly recognized active method-of-use patent estate that controls the principal clinical applications of nafcillin sodium. Its uses in MSSA infections are established clinical applications, and generic labels typically cover the approved antibacterial indications.
When does nafcillin sodium lose exclusivity?
Nafcillin sodium already operates without meaningful market exclusivity. Its original patent and regulatory protection periods expired before the current generic market developed.
| Exclusivity category |
Current commercial relevance |
| Original molecule patent |
Expired |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not material |
| Pediatric exclusivity |
Not material |
| Active formulation exclusivity |
Not material |
| Active method-of-use exclusivity |
Not material |
| Generic competition |
Established |
The principal risk is therefore not generic entry. It is supplier withdrawal, manufacturing disruption, procurement concentration, or substitution by competing antibiotics.
How many patents cover nafcillin sodium?
No material active patent portfolio is generally associated with the core nafcillin sodium injection market. The relevant intellectual-property exposure is likely to involve manufacturing processes, packaging, device components, or contract-manufacturing arrangements rather than blocking pharmaceutical patents.
Patent clearance is consequently less significant than:
- FDA approval status
- Current manufacturing capacity
- Drug-shortage status
- Hospital contracts
- Wholesale acquisition cost
- Group purchasing organization agreements
- Availability of alternative beta-lactams
Which companies manufacture or compete with nafcillin sodium?
The market is supplied by generic injectable manufacturers and hospital-product distributors. Supplier participation can change as companies discontinue presentations, transfer ANDAs, or exit low-margin sterile products.
The relevant competitive set includes:
| Product or class |
Competitive role |
| Nafcillin sodium |
Targeted MSSA therapy; frequent IV dosing |
| Oxacillin injection |
Closest pharmacologic substitute |
| Cefazolin injection |
Commonly preferred MSSA alternative |
| Vancomycin injection |
MRSA coverage and beta-lactam allergy alternative |
| Daptomycin |
Once-daily parenteral alternative for selected serious infections |
| Ceftaroline |
Broad-spectrum cephalosporin with MRSA activity |
| Oral step-down agents |
Used when clinical status permits and susceptibility is appropriate |
Cefazolin is often the strongest commercial competitor. It generally offers less frequent dosing and is widely available through hospital generic channels. Clinical studies and institutional practice have supported cefazolin use for many MSSA bloodstream infections, although treatment selection depends on infection site, inoculum concerns, allergy history, renal function, and physician judgment.[4]
How does nafcillin compare with cefazolin?
Nafcillin has a focused role in serious MSSA infection, but cefazolin often has an operational advantage.
| Attribute |
Nafcillin sodium |
Cefazolin |
| Main target |
MSSA and susceptible staphylococci |
MSSA and broader susceptible Gram-positive coverage |
| Administration |
Often every four to six hours |
Often less frequent |
| Hospital labor burden |
Higher |
Lower |
| Sodium exposure |
Clinically relevant |
Generally lower per treatment regimen |
| Renal dosing |
Primarily hepatic elimination, but monitoring remains important |
Renal dose adjustment commonly required |
| Adverse-effect concerns |
Hepatotoxicity, neutropenia, phlebitis, interstitial nephritis |
Allergy, gastrointestinal effects, renal dosing issues |
| Market position |
Specialized MSSA injectable |
Broad hospital formulary use |
| Price structure |
Generic injectable |
Generic injectable, often stronger purchasing position |
Nafcillin may retain preference for selected MSSA infections because of physician familiarity, historical guideline use, and concern about specific clinical circumstances. Cefazolin’s lower administration burden and favorable hospital economics limit nafcillin volume growth.
What is the Orange Book status of nafcillin sodium?
The Orange Book is relevant for identifying approved products, therapeutic-equivalence evaluations, and any listed patents or exclusivity. Nafcillin sodium’s market profile is that of an established generic injectable with no commercially significant active Orange Book patent barrier.[3]
A Paragraph IV challenge is not a major market event for nafcillin sodium. Paragraph IV litigation typically matters when a generic applicant challenges an unexpired patent listed for a branded reference drug. That structure does not materially describe the current nafcillin sodium market.
What patent litigation affects nafcillin sodium?
There is no widely reported, commercially significant patent litigation presently controlling generic nafcillin sodium access. The absence of meaningful patent litigation reflects the age of the molecule and the lack of a high-value branded product with remaining blocking patents.
Potential disputes would be more likely to involve:
- ANDA ownership or transfer
- Manufacturing contracts
- Product liability
- FDA manufacturing findings
- Supply agreements
- Trademark or packaging issues
These matters would affect individual suppliers rather than the overall legal availability of nafcillin sodium.
What is the financial trajectory for nafcillin sodium?
Nafcillin sodium has a mature, low-growth financial profile. Revenue is primarily linked to hospital utilization and purchasing volume, not price expansion or exclusivity.
Revenue drivers
The principal volume drivers are:
- MSSA infection incidence
- Hospital admissions and inpatient procedures
- Use of intravenous therapy for bacteremia and endocarditis
- Outpatient infusion continuation after discharge
- Hospital formulary decisions
- Temporary shortages of cefazolin or oxacillin
- Availability of generic nafcillin presentations
Revenue constraints
The main constraints are:
- Low generic reimbursement
- Frequent dosing and administration costs
- Substitution by cefazolin
- Hospital group-purchasing pressure
- Limited branded differentiation
- Small revenue contribution per manufacturer
- Sterile manufacturing costs
- Risk of supply interruption
- Lack of patent-based pricing power
Nafcillin can produce acceptable strategic value for a supplier with existing sterile-injectable capacity, but it is unlikely to be a major standalone growth product. Its economics improve when it is manufactured alongside a broader hospital injectable portfolio, allowing fixed plant costs, quality systems, and distribution infrastructure to be shared across products.
How does shortage risk affect financial performance?
Sterile injectables are vulnerable to production interruptions, raw-material constraints, quality investigations, and limited manufacturing capacity. The FDA Drug Shortages database is the primary source for current shortage status, while ASHP maintains a separate shortage reporting resource.[5,6]
A shortage of cefazolin or oxacillin can temporarily increase nafcillin demand. The reverse also applies: if nafcillin supply becomes constrained, hospitals can often shift treatment to cefazolin, oxacillin, or other agents. This substitution limits the duration of any shortage-driven revenue increase.
What generic entry risks exist for nafcillin sodium?
Generic entry risk is already realized. Multiple generic suppliers and therapeutic substitutes keep the market competitive.
The more relevant risks are:
| Risk |
Effect on nafcillin sodium |
| Additional generic supplier entry |
Lower prices and reduced supplier share |
| Supplier exit |
Possible short-term volume transfer to remaining companies |
| Cefazolin preference |
Long-term volume erosion |
| Hospital contract loss |
Rapid account-level revenue decline |
| FDA manufacturing action |
Product interruption or recall |
| Input-cost inflation |
Margin compression |
| Clinical guideline shifts |
Reduced use in MSSA infections |
| Drug shortage |
Temporary volume increase or loss, depending on supplier position |
How strong is the nafcillin sodium patent estate?
The patent estate is weak as a commercial defense. There is no meaningful patent moat around the active ingredient, standard injection formulation, or principal MSSA indications.
A supplier’s competitive strength depends more on execution:
- FDA-compliant sterile manufacturing
- Reliable vial supply
- Competitive contract pricing
- Hospital and distributor relationships
- Product-line breadth
- Effective shortage management
- Low recall and inspection risk
For licensing or acquisition purposes, nafcillin sodium is more valuable as part of a hospital injectable portfolio than as an isolated intellectual-property asset.
What is the outlook for nafcillin sodium?
The base-case outlook is stable to modestly declining volume, with intermittent pricing and supply volatility. MSSA infections will continue to support clinical demand, but cefazolin and other alternatives will limit expansion.
A positive scenario would involve recurring shortages of competing beta-lactams, a supplier securing major hospital contracts, or increased use of nafcillin in outpatient parenteral therapy. A negative scenario would involve further cefazolin substitution, hospital stewardship programs favoring lower-administration-burden regimens, or supplier withdrawal from sterile injectables.
The likely financial pattern is mature generic revenue with limited upside, episodic shortage-related opportunities, and persistent margin pressure.
Key Takeaways
- Nafcillin sodium is an established generic injectable antibiotic for serious MSSA infections.
- No meaningful active composition, formulation, or method-of-use patent barrier controls the market.
- Paragraph IV litigation and Orange Book patent disputes are not major commercial issues.
- Cefazolin is the strongest routine competitive alternative because of dosing convenience and hospital economics.
- Revenue is not generally disclosed as a standalone product category by public manufacturers.
- Sterile manufacturing capacity, hospital contracts, and supply reliability matter more than intellectual property.
- The long-term outlook is stable to modestly declining, with temporary upside during competitor shortages.
- The product is more strategically valuable within a broad hospital-injectable portfolio than as a standalone growth asset.
FAQs
Is nafcillin sodium still commercially available?
Yes. Nafcillin sodium remains an FDA-approved injectable generic, although individual vial sizes, suppliers, and availability can change.
Is nafcillin sodium more expensive than cefazolin?
Acquisition prices vary by supplier and contract. Total treatment cost can be higher with nafcillin because it commonly requires more frequent administration, increasing pharmacy and nursing workload.
Can generic manufacturers launch nafcillin sodium without patent risk?
The core product has no material remaining patent barrier. Manufacturers still face FDA approval, sterile-manufacturing, quality, supply, and commercial-contract requirements.
Is nafcillin sodium used for MRSA?
No. Nafcillin is intended for susceptible staphylococci, particularly MSSA. It is not an effective treatment for MRSA.
Does nafcillin sodium have a biosimilar competitor?
No. Nafcillin sodium is a small-molecule generic drug, not a biologic. Its competitors enter through the generic pathway rather than the biosimilar pathway.
References
- DailyMed. (n.d.). Nafcillin sodium injection prescribing information. U.S. National Library of Medicine.
- Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., J. Rybak, M., Talan, D. A., & Chambers, H. F. (2011). Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections. Clinical Infectious Diseases, 52(3), e18-e55.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Holland, T. L., Arnold, C., Fowler, V. G., Jr. (2014). Clinical management of Staphylococcus aureus bacteremia: A review. JAMA, 312(13), 1330-1341.
- U.S. Food and Drug Administration. (n.d.). Drug shortages database.
- American Society of Health-System Pharmacists. (n.d.). Drug shortages resource center.
